New Delhi: Drug major Cipla’s subsidiary has signed an agreement to fully acquire South Africa’s Mirren (Pty) Ltd for a cash consideration of South African Rand 450 million (approx Rs 228 crore).
Cipla said the acquisition of Mirren, which specializes in over the counter (OTC) pharmaceutical products, will strengthen its market position and help it to accelerate growth within OTC space.
“The company’s wholly-owned subsidiary Cipla Medpro South Africa (Pty) Ltd has signed an agreement to acquire 100 percent stake in Mirren (Pty) Ltd, South Africa,” Cipla said in a regulatory filing.
The transaction required approval by the South African Competition Commission and is expected to be completed before September 30, 2018, Cipla said.
“Cash consideration of South African Rand 450 million to be paid on closing of the transaction,” the company said.
Mirren (Pty) Ltd, South Africa had a turnover of South African Rand 152.1 million for the financial year ended on February 28, 2018. It has a presence in South Africa, Namibia, and Botswana.
Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751